NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
Show detailsBibliographic details: Zhu Y, Tang RK, Zhao P, Zhu SS, Li YG, Li JB. Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials. European Journal of Gastroenterology and Hepatology 2012; 24(5): 487-494. [PubMed: 22465970]
Abstract
OBJECTIVES: Several trials have demonstrated that oral delayed-release mesalamine might be administered once daily. We aimed to conduct a meta-analysis to investigate this.
METHODS: A comprehensive and multiple-source literature search was carried out. Only randomized-controlled trials (RCTs) were investigated by comparing a once daily-dosing regime with a divided (twice or thrice daily)-dosing regime of oral delayed-release mesalamine formulations for induction or maintenance of remission in patients with mild-to-moderate ulcerative colitis. The quality of RCTs was assessed using the Jadad scores. Meta-analysis of pooled odds ratios was carried out using Review Manager 5.1.
RESULTS: Nine RCTs were finally included. With regard to meta-analyses for induction trials, there were no significant differences for all comparisons between the once daily and the divided groups, including maintenance of just clinical remission (P=0.52) and just endoscopic remission (P=0.23), maintenance of combined clinical and endoscopic remission (P=0.78), and the overall incidence of adverse events (P=0.61). With regard to meta-analyses for maintenance trials, there were also no significant differences for all comparisons between once daily and divided groups, including maintenance of just clinical remission (P=0.73) and just endoscopic remission (P=0.43), maintenance of combined clinical and endoscopic remission (P=0.43), the overall incidence of adverse events (P=0.12) as well as compliance with the prescribed medication (P=0.34).
CONCLUSION: The present work showed that oral delayed-release mesalazine administered as a single or a divided dose demonstrated a good safety profile, which was well tolerated and effective as either maintenance or induction treatment. High clinical and/or endoscopic remission rates can be achieved with once-daily dosing.
- Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.[Gastroenterology. 2010]Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, et al. Gastroenterology. 2010 Apr; 138(4):1286-96, 1296.e1-3. Epub 2010 Jan 11.
- Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.[Clin Gastroenterol Hepatol. 2009]Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.Dignass AU, Bokemeyer B, Adamek H, Mross M, Vinter-Jensen L, Börner N, Silvennoinen J, Tan G, Pool MO, Stijnen T, et al. Clin Gastroenterol Hepatol. 2009 Jul; 7(7):762-9. Epub 2009 Apr 16.
- Review Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.[Cochrane Database Syst Rev. 2012]Review Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.Feagan BG, Macdonald JK. Cochrane Database Syst Rev. 2012 Oct 17; 10:CD000543. Epub 2012 Oct 17.
- Review Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.[Cochrane Database Syst Rev. 2016]Review Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK. Cochrane Database Syst Rev. 2016 Apr 21; 4(4):CD000543. Epub 2016 Apr 21.
- Review Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.[Cochrane Database Syst Rev. 2012]Review Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.Feagan BG, Macdonald JK. Cochrane Database Syst Rev. 2012 Oct 17; 10:CD000544. Epub 2012 Oct 17.
- Can oral 5-aminosalicylic acid be administered once daily in the treatment of mi...Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews
Your browsing activity is empty.
Activity recording is turned off.
See more...